


## Globin mRNA reduction for whole-blood transcriptome sequencing

Kaarel Krjutškov<sup>1,3</sup>, Mariann Koel<sup>2,4</sup>, Anne Mari Roost<sup>2</sup>, Shintaro Katayama<sup>1</sup>, Elisabet Einarsdottir<sup>1,3</sup>, Eeva-Mari Jouhilahti<sup>1</sup>, Cilla Söderhäll<sup>1,5</sup>, Ülle Jaakma<sup>2,6</sup>, Mario Plaas<sup>7</sup>, Liselotte Vesterlund<sup>1</sup>, Hannes Lohi<sup>3</sup>, Andres Salumets<sup>2,7,8</sup>, Juha Kere<sup>1,3</sup>



	GlobinClear™ Kit <sup>1</sup>	Globin-Zero™ Kit <sup>2</sup>	GlobinLock
Principle	Specific oligonucleotide hybridization and biotin-streptavidin magnetic capture	Specific oligonucleotide hybridization. The capture principle is not published	Specific oligonucleotide hybridization and globin mRNA blocking prior oligo-T priming
Isolation technology	Magnetic capture	Magnetic capture	Specific blocking
Need of previous DNase I treatment	No	Yes	No
Enzymatic treatment during capture	No	No	No
Globin reduction rate	>95%	>98%	>91% <sup>3</sup>
Need of additional equipment	Magnetic stand, hybridization block	Magnetic stand, hybridization block	No
Starting material (total blood RNA, µg)	1 - 10	1 - 5	0.01 - 0.1
Input concentration (ng/µl)	≥70	≥38	≥10
Purification time (min)	90	90	10
Downstream cDNA synthesis by random primer	+	+	-
Downstream cDNA synthesis by oligo-T primer	+	+	+
Purification before downstream application	Yes	Yes	No
Price per single reaction <sup>4</sup> (USD)	35	96	0.5 <sup>3</sup> - 4.5 <sup>5</sup>
High-throughput compatible	Yes	No	Yes
PubMed references (PubMed ID)	17065423, 22257641, 20477359, 17303101	NA	NA

<sup>1</sup> [www.thermofisher.com/order/catalog/product/AM1980](http://www.thermofisher.com/order/catalog/product/AM1980)

<sup>2</sup> [support.illumina.com/sequencing/sequencing\\_kits/globin-zero-gold.html](http://support.illumina.com/sequencing/sequencing_kits/globin-zero-gold.html)

<sup>3</sup> GlobinLock LNA oligonucleotides


<sup>4</sup> manufacturer's suggested retail price in Sweden

<sup>5</sup> circular GlobinLock oligonucleotides

**Supplementary Figure 1.** Comparison of two commercially available globin mRNA reduction assays (GLOBINclear™ and Globin-Zero™) based on manufacturer's product information from official webpage. In addition, GlobinLock principle and parameters are depicted.







**Supplementary Figure 4.** The prevalence of globin mRNAs from different species was reduced by type 3'DNA long GlobinLock oligonucleotides, quantified by qPCR. NA indicates the inability to detect the specific globin with unique primers using a SYBR green qPCR assay. Template dilutions (10×) were used in this relative qPCR design and therefore the reduction effect up to ten is measured accurately according to existing dilution factor but fold change values above ten are out of the reported quantification range.

**Supplementary Table 1.** Used GlobinLock oligonucleotides with specific modifications and purifications. In addition, qPCR primers, barcoded 48-plex template-switching oligonucleotides for 48-plex RNA-seq experiment and globin cloning primers of different species are listed.

>>> Attached as a separate file "Suppl Table 1"

**Supplementary Table 2.** The specificity of GlobinLock with 1–100 ng of whole-blood RNA, using two artificial spike-in molecules. One-way ANOVA analysis together with *t*-test *p*-values to measure the significance based on two spike-in molecule (Spike-1 and Spike-2) detection rates at different whole-blood RNA input levels.

Spike-1					t-test p-value			
					+	+	+	
GlobinLock	Blood-RNA input	C <sub>T</sub> values	1 ng	50 ng	100 ng			
			24.827	24.873	24.772			
			24.743	24.844	24.761			
			24.72	24.766	24.709			
+	1 ng	24.827	24.743	24.72	NA	0.2310	0.6945	
+	50 ng	24.873	24.844	24.766	0.2310	NA	0.0982	
+	100 ng	24.772	24.761	24.709	0.6945	0.0982	NA	

*P*=0.1910 by one-way ANOVA

Spike-2					t-test p-value			
					+	+	+	
GlobinLock	Blood-RNA input	C <sub>T</sub> values	1 ng	50 ng	100 ng			
			24.265	24.119	24.588			
			24.311	24.244	24.195			
			24.324	24.250	24.206			
+	1 ng	24.265	24.311	24.324	NA	0.1077	0.8312	
+	50 ng	24.119	24.244	24.250	0.1077	NA	0.4092	
+	100 ng	24.588	24.195	24.206	0.8312	0.4092	NA	

*P*=0.5404 by one-way ANOVA

**Supplementary Table 3.** The statistics for GL RNA sequencing results over five GL conditions and the control. RNA-seq data QC parameters from mapping (No. of raw reads per sample (average)) to (mRNA 5'-end capture rate (%)). The data were analyzed with unique molecular identifier (UMI) correction and without. The results described in the manuscript are without UMI correction. The analytical pipeline details are described in Methods and <https://github.com/shka/STRTprep>

>>> Attached as a separate file "Suppl Table 3"

**Supplementary Table 4.** Uniquely detected genes without different GlobinLock oligonucleotides. The top 10 uniquely expressed genes under different GlobinLock conditions and the GlobinLock-negative control. The mRNA's 3'-most sequences are depicted and

compared with GlobinLock sequences to find possible interactions. BLASTN scores indicated very low specificity because the values remained <33 in a 100 scale.

>>> *Attached as a separate file "Suppl Table 4"*

**Supplementary Table 5.** The detected genes with normalized prevalence and 95% confidence intervals. The "Type" represents the type of tested GlobinLock oligonucleotides or negative control.

>>> *Attached as a separate file "Suppl Table 5"*

**Supplementary Table 6.** Alignment of high-quality Sanger re-sequencing of dog and zebrafish clones compared to the reference and GlobinLock molecule. Novel motifs or deletions are marked in red.

>>> *Attached as a separate file "Suppl Table 6"*

**Supplementary Table 7.** The high-quality raw data of Sanger re-sequencing.

>>> *Attached as a separate file "Suppl Table 7"*